2021
09
Presentation of final data from Phase 1 study of ISU104 at ESMO
07
The grant of a patent for Barecetamab(ISU104) by the EPO(European Patent Office)
05
The grant of a patent for Brecetamab(ISU104) by the CNIPA(China National Intellectual Property Administration)
04
Manufacturing consortium for Russia’s Sputnik V COVID-19 vaccine with GL Rapha and RDIF(Russian Direct Investment Fund)
03
Publication of data from preclinical study with Barecetamab(ISU104), Molecular Cancer Therapeutics
Completion of the Phase 1 study of Abcertin®(Australia)
02
Publication of data from the Phase 1/2 clinical trial of Dalcinonacog alfa(ISU304), Journal of Thrombosis and Haemostasis
Approval of the International Nonproprietary Name(INN) Barecetamab for ISU104
2020
12
The grant of a patent for ISU104 by Indonesia DGIP(Directorate General of Intellectual Property)
11
Out-licenses agreement for ISU305 to Russian pharmaceutical company Pharmasyntez
09
Clinical data presentation from the Phase 1 Part 2 study of ISU104 at the ESMO
08
Completion of the Phase 1 clinical trial of ISU305(Australia and New Zealand)
06
Preclinical data presentation for ISU104 at the AACR
Presentation of final data from Phase 2 study of ISU304 at the WFH
04
The grant of a patent for ISU104 by the CIPO(Canadian Intellectual Property Office)
2019
12
Initiation of the Phase 1 clinical trial for Abcertin®(Australia)
11
The grant of a patent for ISU104 by Federal Service for Intellectual Property of the Russian Federation, ROSPATENT
09
Clinical data presentation from the Phase 1 Part 1 study of ISU104 at the ESMO(European Society for Medical Oncology)
07
The grant of a patent for ISU104 by the USPTO(United States Patent and Trademark Office)
06
The grant of a patent for ISU104 by the IP Australia
03
Initiation of the Phase 1 clinical trial for ISU305(Australia and New Zealand)
2018
12
The grant of a patent for ISU104 by the KIPO
10
New product launch in Korea: Trintop® for the treatment of Wilson’s disease
05
Clinical data presentation from the Phase 1/2 study for ISU304 at the WFH(World Federation of Hemophilia)
04
Preclinical data presentation for ISU104 at the AACR(American Association for Cancer Research)
03
The grant of a patent for ISU304 by the KIPO(Korean Intellectual Property Office)
Completion of new GMP manufacturing facility in Yongin, Gyeonnggi
01
ISU104 is supported and funded by the KDDF(Korea Drug Development Fund).
The grant of a patent for ISU104 by the TIPO(Taiwan Intellectual Property Office)